[
    {
        "molecule_name": "BMY7378",
        "protein_target_name": "α1D adrenoceptor",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "KB",
        "value": "2.95",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "prazosin (PZS)",
        "protein_target_name": "α1A adrenoceptor",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "Kd",
        "value": "0.46",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "prazosin (PZS)",
        "protein_target_name": "α1A adrenoceptor",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "Kd",
        "value": "56.5",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "prazosin (PZS)",
        "protein_target_name": "α1B-adrenoceptor",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "Kd",
        "value": "0.34",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "[3H]-prazosin",
        "protein_target_name": "α1A adrenoceptors",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "Kd",
        "value": "0.46",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "[3H]-prazosin",
        "protein_target_name": "α1A adrenoceptors",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "Kd",
        "value": "56.5",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "[3H]-prazosin",
        "protein_target_name": "α1B adrenoceptors",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "Kd",
        "value": "0.34",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "LDT65",
        "protein_target_name": "α2A receptors",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "log IC50",
        "value": "-5.60",
        "unit": null,
        "is_logarithmic": true,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "LDT65",
        "protein_target_name": "α2A receptors",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "Ki",
        "value": "1.5",
        "unit": "µM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "LDT66",
        "protein_target_name": "α2A receptors",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "log IC50",
        "value": "-5.92",
        "unit": null,
        "is_logarithmic": true,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "LDT66",
        "protein_target_name": "α2A receptors",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "Ki",
        "value": "0.8",
        "unit": "µM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "LDT67",
        "protein_target_name": "α2A receptors",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "log IC50",
        "value": "-6.10",
        "unit": null,
        "is_logarithmic": true,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "LDT67",
        "protein_target_name": "α2A receptors",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "Ki",
        "value": "0.5",
        "unit": "µM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "LDT68",
        "protein_target_name": "α2A receptors",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "log IC50",
        "value": "-6.01",
        "unit": null,
        "is_logarithmic": true,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "LDT68",
        "protein_target_name": "α2A receptors",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "Ki",
        "value": "0.6",
        "unit": "µM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "LDT2",
        "protein_target_name": "5-HT1A receptors",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "log CI50",
        "value": "-8.52",
        "unit": null,
        "is_logarithmic": true,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "LDT2",
        "protein_target_name": "5-HT1A receptors",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "Ki",
        "value": "1.24e-9",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "LDT3",
        "protein_target_name": "5-HT1A receptors",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "log CI50",
        "value": "-8.56",
        "unit": null,
        "is_logarithmic": true,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "LDT3",
        "protein_target_name": "5-HT1A receptors",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "Ki",
        "value": "1.13e-9",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "LDT8",
        "protein_target_name": "5-HT1A receptors",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "log CI50",
        "value": "-10.24",
        "unit": null,
        "is_logarithmic": true,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "LDT8",
        "protein_target_name": "5-HT1A receptors",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "Ki",
        "value": "2.37e-11",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "LDT62",
        "protein_target_name": "5-HT1A receptors",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "log IC50",
        "value": "-6.47",
        "unit": null,
        "is_logarithmic": true,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "LDT62",
        "protein_target_name": "5-HT1A receptors",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "Ki",
        "value": "147",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "LDT65",
        "protein_target_name": "5-HT1A receptors",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "log IC50",
        "value": "-7.42",
        "unit": null,
        "is_logarithmic": true,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "LDT65",
        "protein_target_name": "5-HT1A receptors",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "Ki",
        "value": "18",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "LDT66",
        "protein_target_name": "5-HT1A receptors",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "log IC50",
        "value": "-7.93",
        "unit": null,
        "is_logarithmic": true,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "LDT66",
        "protein_target_name": "5-HT1A receptors",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "Ki",
        "value": "5",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "LDT67",
        "protein_target_name": "5-HT1A receptors",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "log IC50",
        "value": "-7.42",
        "unit": null,
        "is_logarithmic": true,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "LDT67",
        "protein_target_name": "5-HT1A receptors",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "Ki",
        "value": "18",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "LDT65",
        "protein_target_name": "5-HT1A receptors",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "Ki high",
        "value": "18",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "LDT65",
        "protein_target_name": "5-HT1A receptors",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "Ki low",
        "value": "21.1",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "LDT66",
        "protein_target_name": "5-HT1A receptors",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "Ki high",
        "value": "5",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "LDT66",
        "protein_target_name": "5-HT1A receptors",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "Ki low",
        "value": "9.01",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "LDT67",
        "protein_target_name": "5-HT1A receptors",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "Ki high",
        "value": "18",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "LDT67",
        "protein_target_name": "5-HT1A receptors",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "Ki low",
        "value": "8.62",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "LDT68",
        "protein_target_name": "5-HT1A receptors",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "Ki high",
        "value": "9",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "LDT68",
        "protein_target_name": "5-HT1A receptors",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "Ki low",
        "value": "3.1",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "LDT2",
        "protein_target_name": "5-HT2A receptors",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "log IC50",
        "value": "-7.13",
        "unit": null,
        "is_logarithmic": true,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "LDT2",
        "protein_target_name": "5-HT2A receptors",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "Ki",
        "value": "4.74e-8",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "LDT3",
        "protein_target_name": "5-HT2A receptors",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "log IC50",
        "value": "-7.15",
        "unit": null,
        "is_logarithmic": true,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    },
    {
        "molecule_name": "LDT3",
        "protein_target_name": "5-HT2A receptors",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "Ki",
        "value": "4.52e-8",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. We conducted experiments with BMY7378 50 nM, α1D adrenoceptor antagonist used as positive control, and obtained a value of KB = 2.95 nM, consistent with the literature (CARROLL et al, Bioorg Med Chem Lett, 11:1119 - 1121, 2001).\n2. Compared with BMY7378 (KB=2.95 nM) affinity for this receptor is greater for the LDT derivative 5 and 8 (KB = 0.57 and 0.16, respectively, * P &lt;0.05).\n3. For the calculation of the Ki of the LTD's it was used the Cheng-Prusoff equation, where for prazosin (PZS) Kd values were 0.46 nM and 56.5 nM for sites of high and low affinity, respectively to α1A adrenoceptor, and it was used Kd = 0.34 nM for α1B-adrenoceptor.\n4. Kd values of [3H]-prazosin to α1A adrenoceptors were 0.46 nM and 56.5 nM for sites with high and low affinities, respectively (n = 3), and α1B adrenoceptors the Kd value was 0,34 nM (n = 3), in agreement with literature (SHIBATA and cols., Mol. Pharmacol., 48:250-258, 1995).\n5. The Ki obtained values were summarized in the following Tables 3 to 5 below, including LDT2 with Ki = 1.57 x 10-8 M, LDT3 with Ki = 4.63 x 10-9 M, and LDT4 with Ki = 8.81 x 10-9 M.\n6. LDT66, LDT68 and LDT69 derivatives (Ki equal to 43, 38 and 33 nM, respectively) showed affinity six to eight times higher (P &lt;0.01) than LDT62 (Ki = 261 nM) (Table 5).\n7. Table 6: Pharmacological Parameters of the LDT's (65-68) in α2A receptors, including LDT65 with log IC50 = -5.60 ± 0.06 and Ki = 1.5 µM, LDT66 with log IC50 = -5.92 ± 0.06 and Ki = 0.8 µM, LDT67 with log IC50 = -6.10 ± 0.06 and Ki = 0.5 µM, and LDT68 with log IC50 = -6.01 ± 0.03 and Ki = 0.6 µM.\n8. Table 7: Pharmacologicalparameters ofLDT's (2-6, 8, 245) for 5-HT1A receptors, including LDT2 with log CI50 = -8.52 ± 0.03 and Ki = 1.24 x 10-9 M, LDT3 with log CI50 = -8.56 ± 0.07 and Ki = 1.13 x 10-9 M, and LDT8 with log CI50 = -10.24 ± 0.71 and Ki = 2.37 x 10-11 M.\n9. Table 8: Pharmacological Parameters LDT' s (62-70, 39) in the 5-HT1A, including LDT62 with log IC50 = -6.47 ± 0.10 and Ki = 147 nM, LDT65 with log IC50 = -7.42 ± 0.09 and Ki = 18 nM, LDT66 with log IC50 = -7.93 ± 0.20 and Ki = 5 nM, and LDT67 with log IC50 = -7.42 ± 0.19 and Ki = 18 nM.\n10. Table 9. intrinsic activity estimative of LDT 65-68 in 5-HT1A receptors, including LDT65 with Ki high = 18 nM and Ki low = 21.1 nM, LDT66 with Ki high = 5 nM and Ki low = 9.01 nM, LDT67 with Ki high = 18 nM and Ki low = 8.62 nM, and LDT68 with Ki high = 9 nM and Ki low = 3.1 nM.\n11. Table 10: Pharmacological Parameters LDT's (2-6 and 8) with 5-HT2A receptors, including LDT2 with log IC50 = -7.13 ± 0.11 and Ki = 4.74 x 10-8 M, LDT3 with log IC50 = -7.15 ± 0.22 and Ki = 4.52 x 10-8 M, and LDT8 with log IC50 = -7.16 ± 0.06 and Ki = 4.42 x 10-8 M.\n12. Table 11: pharmacological parameters of the LDT's (62-70, 39) on 5-HT2A receptors, including LDT62 with log IC50 = -5.00 ± 0.16 and Ki = 6.41 nM, LDT65 with log IC50 = -5.34 ± 0.09 and Ki = 2.93 nM, LDT66 with log IC50 = -5.57 ± 0.16 and Ki = 1.72 nM, and LDT67 with log IC50 = -5.53 ± 0.13 and Ki = 1.89 nM.\n13. Table 12: Pharmacological parameters of the LDT's on α2A receptors, including LDT3 with log IC50 = -5.96 ± 0.09 and Ki = 0.935 µM, LDT5 with log IC50 = -6.53 ± 0.05 and Ki = 0.248 µM, LDT6 with log IC50 = -6.22 ± 0.12 and Ki = 0.552 µM, and LDT8 with log IC50 = -5.7 ± 0.20 and Ki = 0.16 µM.\n14. Table 13. Intrinsic activity estimate of LDT's on 5-HT1A receptors, including LDT3 with Ki high = 1.79 nM and Ki low = 1.99 nM, LDT5 with Ki high = 3.89 nM and Ki low = 8.12 nM, LDT8 with Ki high = 0.018 nM and Ki low = 0.0623 nM.\n15. Table 14: Pharmacological Parameters LDT's on muscarinic receptors, including LDT3 with log IC50 = -4.26 ± 0.07 and Ki = 56.7 µM, LDT5 with log IC50 = -3.97 ± 0.06 and Ki = 108 µM, LDT6 with log IC50 = -4.48 ± 0.07 and Ki = 33.9 µM, and LDT8 with log IC50 = -4.5 ± 0.05 and Ki = 10.8 µM.\n16. Table 15: pharmacological parameters of LDT's on D2 dopaminergic receptors, including LDT3 with log IC50 = -6.73 ± 0.13 and Ki = 0.186 µM, LDT5 with log IC50 = -7.05 ± 0.04 and Ki = 0.1 µM, LDT8 with log IC50 = -7.91 ± 0.01 and Ki = 0.004 µM, and LDT66 with log IC50 = -6.92 ± 0.11 and Ki = 0.04 µM."
    }
]